>>> US Gapping up

Gapping up
In reaction to strong earnings/guidance:

DEST +21.3%, (Destination Maternity report Q3-to-date E-commerce sales +50%; operational initiatives are expected to deliver $10 to $11 million in run-rate savings beginning in fiscal year 2018), PSO +6.3%,TTS +3.6%, KMG +3%, (also commenced public offering of 2,600,000 shares of its common stock), UNH +1.6%, BCLI +1.5%, GWW +1.5%, MS+1.3%, GS +1.2%, JNJ +1.1%, NFLX +1%, OMC +0.6%, CSX +0.5%

M&A news:

SNCR +18.1% (Concludes strategic alternatives process; to Divest non-core assets through agreement to sell Intralinks Business to Siris)
MNGA +14.9% (announces the sale of an additional gasification unit for $1.58 mln)
SRAX +1% (has engaged financial advisors to explore strategic alternatives for the SRAXmd busines)

Other news:

DFFN +41% (receives final protocol guidance from FDA for a Phase 3 clinical trial with TSC)
EYES +20.4% (received approval from Bundesinstitut für Arzneimittel und Medizinprodukte)
IMDZ +7.9% (plans to initiate a pivotal Phase 3 trial to support a BLA for CMB305, a novel cancer vaccine, in patients with synovial sarcoma following 'productive discussions' w/ the FDA)
TRXC +6.8% (discloses that the clearance from the FDA for its Senhance Surgical Robotic System triggers an acceleration of the expiration date of the Series A Warrants to Purchase Common Stock to October 31)
RXDX +6% (EMA has granted Priority Medicines designation for entrectinib)
SAVE +5.3% (Spirit Airlines reports September traffic, provides updated Q3 guidance -- Q3 revenue per available seat mile is estimated to be down approximately 6.5% y/y)
TNXP +4.3% (receipt of official minutes from a chemistry, manufacturing and controls guidance meeting with the FDA regarding the CMC data required to support the Tonmya)
KALV +4% (10% owner/Director RA Capital Management dislclosed the purchase of 850K shares)
MDXG +1.8% ( has been notified by the FDA that its IND Phase 2B clinical study for osteoarthritis of the knee may proceed)
ULTA +0.7% (Director discloses the purchase of additional shares)
TEVA +0.7% (submits BLA to the FDA for fremanezumab),

Analyst comments: